LLY - Eli Lilly and Company

NYSE - NYSE Precio retrasado. Divisa en USD.

Eli Lilly and Company

Lilly Corporate Center
Indianapolis, IN 46285
United States
317 276 2000
https://www.lilly.com

Sector(es)Healthcare
IndustriaDrug Manufacturers—General
Empleados a tiempo completo39,000

Ejecutivos clave

NombreTítuloPagarEjecutadoAño de nacimiento
Mr. David A. RicksChairman, CEO & Pres4.42MN/D1968
Ms. Anat AshkenaziExec. VP & CFO2.13MN/D1973
Dr. Daniel M. Skovronsky M.D., Ph.D.Exec. VP, Chief Scientific & Medical Officer and Pres of Lilly Research Laboratories2.72MN/D1974
Ms. Anat Hakim J.D.Exec. VP, Gen. Counsel & Sec.1.98MN/D1969
Mr. Patrik JonssonEVP, Chief Customer Officer, Pres of Lilly USA & Lilly Immunology1.67MN/D1967
Mr. Donald A. ZakrowskiChief Accounting Officer & VP of Fin.N/DN/DN/D
Mr. Diogo RauEVP & Chief Information and Digital OfficerN/DN/DN/D
Mr. Alonzo WeemsEVP of Enterprise Risk Management and Chief Ethics & Compliance OfficerN/DN/D1971
Ms. Leigh Ann PuseyExec. VP of Corp. Affairs & CommunicationsN/DN/D1963
Mr. Eric DozierExec. VP of HR & DiversityN/DN/D1967
Los importes son a partir de 31 de diciembre de 2022 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Pago corresponde al salario, las bonificaciones, etc. Ejecutado corresponde al valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Gestión corporativa

La calificación ISS Governance QuickScore de Eli Lilly and Company a partir del 1 de junio de 2023 es 5. Las puntuaciones principales son Auditoría: 3; Junta: 5; Derechos del accionista: 9; Compensación: 1.

Las puntuaciones de la gestión corporativa son cortesía de Servicios de accionistas institucionales (ISS). Las puntuaciones indican una posición decil en relación con el índice o la región. Una puntuación decil 1 indica que el riesgo de gestión es menor, mientras que una puntuación decil 10 indica que el riesgo de gestión es mayor.